phosphonoacetic acid has been researched along with Eye Infections, Viral in 22 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
Eye Infections, Viral: Infections of the eye caused by minute intracellular agents. These infections may lead to severe inflammation in various parts of the eye - conjunctiva, iris, eyelids, etc. Several viruses have been identified as the causative agents. Among these are Herpesvirus, Adenovirus, Poxvirus, and Myxovirus.
Excerpt | Relevance | Reference |
---|---|---|
"In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
"To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
"The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 8.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
"Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
"Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
"Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 6.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
"In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
"To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
"The use of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) is limited by marrow toxicity and by the development of resistance to this agent in CMV strains capable of causing progressive disease." | 4.78 | Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet. ( Jacobson, MA, 1992) |
"Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
"Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
"Foscarnet has a low solubility and a high degree of ionization at physiologic pH, requiring it to be administered in higher doses and larger volumes." | 2.38 | Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet. ( Jacobson, MA; O'Donnell, JJ, 1991) |
" Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 22 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Healy, B | 1 |
Masur, H | 1 |
Heinemann, MH | 1 |
Polis, MA | 2 |
Jacobson, MA | 4 |
Jabs, DA | 1 |
Salit, IE | 1 |
Wilson, RJ | 1 |
Morris, DJ | 1 |
Drew, WL | 1 |
Feinberg, J | 1 |
O'Donnell, JJ | 2 |
Whitmore, PV | 1 |
Miner, RD | 1 |
Parenti, D | 1 |
MacGregor, RR | 1 |
Graziani, AL | 1 |
Weiss, R | 1 |
Grunwald, JE | 1 |
Gambertoglio, JG | 1 |
Palestine, AG | 1 |
De Smet, MD | 1 |
Baird, BF | 1 |
Falloon, J | 1 |
Kovacs, JA | 1 |
Davey, RT | 1 |
Zurlo, JJ | 1 |
Zunich, KM | 1 |
Davis, M | 1 |
Marwick, C | 1 |
Nightingale, SL | 1 |
Nelson, MR | 1 |
Barter, G | 1 |
Hawkins, D | 1 |
Gazzard, BG | 1 |
Henderly, DE | 1 |
Jampol, LM | 1 |
Minor, JR | 1 |
Baltz, JK | 1 |
Farese, RV | 1 |
Schambelan, M | 1 |
Hollander, H | 1 |
Stringari, S | 1 |
Deray, G | 1 |
Katlama, C | 1 |
Dohin, E | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
6 reviews available for phosphonoacetic acid and Eye Infections, Viral
Article | Year |
---|---|
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Approaches to the treatment of cytomegalovirus retinitis: ganciclovir and foscarnet.
Topics: Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Combination; Eye Infections, Viral; Fosc | 1991 |
Diagnosis and treatment of cytomegalovirus retinitis.
Topics: Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differential; Eye Infections, Viral; Foscar | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
2 trials available for phosphonoacetic acid and Eye Infections, Viral
Article | Year |
---|---|
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
14 other studies available for phosphonoacetic acid and Eye Infections, Viral
Article | Year |
---|---|
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Why was treatment of cytomegalovirus retinitis randomized?
Topics: Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Foscarnet; Ganciclovir; Humans; | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Prevention of foscarnet nephrotoxicity.
Topics: Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Viral; Female; Fluid Therapy; F | 1990 |